LIG4 Antikörper (N-Term)

Produktnummer ABIN1881497

Der Kaninchen Polyklonal Anti-LIG4-Antikörper wurde für WB validiert. Er ist geeignet, LIG4 in Proben von Human zu detektieren.

Kurzübersicht für LIG4 Antikörper (N-Term) (ABIN1881497)

Target: LIG4 (Ligase IV, DNA, ATP-Dependent (LIG4))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LIG4 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Klon: RB40331

Produktdetails anti-LIG4 Antikörper

Bindungsspezifität: AA 239-267, N-Term

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This LIG4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 239-267 amino acids from the N-terminal region of human LIG4.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Details zu LIG4

Target: LIG4 (Ligase IV, DNA, ATP-Dependent (LIG4))

Andere Bezeichnung: LIG4

Hintergrund: Efficiently joins single-strand breaks in a double-stranded polydeoxynucleotide in an ATP-dependent reaction. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. The LIG4-XRCC4 complex is responsible for the NHEJ ligation step, and XRCC4 enhances the joining activity of LIG4. Binding of the LIG4-XRCC4 complex to DNA ends is dependent on the assembly of the DNA-dependent protein kinase complex DNA-PK to these DNA ends.

Molekulargewicht: 103971

NCBI Accession: NP_001091738, NP_002303, NP_996820

UniProt: P49917

Pathways: DNA Reparatur, Production of Molecular Mediator of Immune Response